Solara Active Pharma Sciences
645.15
-12.10(-1.84%)
Market Cap₹2,376.20 Cr
PE Ratio96.68
IndustryHealthcare
Company Performance:
1D-1.84%
1M+1.27%
6M+25.93%
1Y+6.72%
5Y+7.13%
View Company Insightsright
Latest news about Solara Active Pharma Sciences
Solara Active Pharma Sciences Reports Strong Q1 with 15% Revenue Growth and Highest PAT in 12 Quarters 2 hours ago Today
Solara Active Pharma Sciences Limited reported robust Q1 results with revenue of INR 320.00 crores, up 15% quarter-on-quarter. EBITDA grew 13% quarter-on-quarter to INR 57.00 crores. The company achieved its highest PAT in 12 quarters at INR 10.50 crores. Debt was reduced by INR 143.00 crores, bringing the net debt-to-EBITDA ratio to 2.7x. Solara has reduced its dependence on ibuprofen to about 30% of business. The company is operating at 60-65% capacity utilization and expects 10% revenue growth and 15-20% EBITDA growth. Plans to demerge the CRAMS business are progressing, with expectations to grow this segment to INR 400.00-500.00 crores in 3-4 years.
Solara Active Pharma Reports Strong Q1 Results with 15% Revenue Growth and Positive Earnings 4 days ago
Solara Active Pharma Sciences Shifts Focus to High-Value Markets, Plans Demerger Jul 06, 2025
Solara Active Pharma Sciences Downgrades FY25 Financial Outlook May 15, 2025
Solara Active Pharma Sciences Reports Improved Q4 Performance Despite Revenue Dip May 15, 2025
More news about Solara Active Pharma Sciences
12May 25
Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors
Solara Active Pharma Sciences' Ambernath facility has successfully passed a United States Food and Drug Administration (USFDA) inspection without any Form 483 observations. This outcome indicates full compliance with USFDA's regulatory standards, potentially boosting the company's regulatory confidence, market reputation, and business opportunities in the U.S. pharmaceutical market. The clean inspection ensures operational continuity and reflects the high quality of Solara's manufacturing processes and compliance systems.
10May 25
Solara Active Pharma's Ambernath Facility Passes USFDA Inspection with Flying Colors
Solara Active Pharma Sciences Limited's Ambernath facility successfully completed a United States Food and Drug Administration (USFDA) inspection with no Form 483 observations. This outcome demonstrates the facility's compliance with stringent regulatory standards and could boost market confidence, potentially leading to expanded business opportunities in regulated markets, particularly the United States. The clean inspection report highlights Solara's commitment to maintaining high-quality manufacturing standards in the pharmaceutical industry.
24Feb 25
Solara Active Pharma Sciences to Shut Down Brazilian Subsidiary
Solara Active Pharma Sciences' board has approved the closure of its subsidiary in Brazil, Solara Active Pharma Sciences Ltda. This decision marks a significant shift in the company's international strategy, potentially impacting its operations in the South American market. The closure could lead to reduced operational costs, a shift in focus to other markets, and possible restructuring of the global supply chain. The move signals a strategic realignment for Solara, with potential implications for its financial performance and market position.
21Feb 25
Solara Active Pharma Sciences Announces Major Restructuring and Leadership Changes
Solara Active Pharma Sciences Limited has announced significant corporate changes following a board meeting on February 21, 2025. The company will close its non-operational Brazilian subsidiary. Key leadership appointments include Sandeep Rao as new MD & CEO, Sarat Kumar as CFO, and Vishal Mathur as CBO. The board approved granting 3,50,000 stock options to employees at Rs. 375 per option. Various committees have been reconstituted to reflect these changes.
1 Year Returns:+6.72%
Industry Peers
Sun Pharmaceutical
1,710.50
(+0.49%)
Divis Laboratories
6,676.50
(+1.40%)
Cipla
1,574.00
(+0.13%)
Torrent Pharmaceuticals
3,768.10
(+4.01%)
Dr Reddys Laboratories
1,299.80
(+0.96%)
Mankind Pharma
2,554.70
(+0.52%)
Zydus Life Science
994.85
(+1.50%)
Lupin
1,984.60
(+1.23%)
Abbott
34,710.00
(+5.52%)
Aurobindo Pharma
1,158.10
(+2.76%)